Table 2 General demographic characteristics of the Urban Health Study population genotyped for common variants in MBL2
From: MBL2and Hepatitis C Virus Infection among Injection Drug Users
European Americans | African Americans | |||||
|---|---|---|---|---|---|---|
HCV RNA Negative (n = 109) | HCV RNA Positive (n = 344) | P | HCV RNA Negative (n = 89) | HCV RNA Positive (n = 310) | P | |
Gender, male (%) | 68 (62.4) | 247 (71.8) | 0.06 | 54 (68.7) | 192 (61.2) | 0.83 |
Age at blood draw, median years (range) | 43 (25–63) | 43 (23–65) | 0.46 | 47 (31–64) | 47 (28–82) | 0.16 |
Duration of IDU, median years (range) | 23 (5–41) | 24 (10–49) | 0.83 | 26 (8–44) | 27 (11–51) | 0.13 |
HIV-1 serostatus | ||||||
Seropositive | 5 (4.6) | 41 (11.9) | 8 (9.0) | 36 (11.6) | ||
Seronegative | 104 (95.4) | 303 (88.1) | 0.03 | 81 (91.0) | 274 (88.4) | 0.49 |